media – Page 10 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Another GLP-1 drug king, is it on the way?

Recently, the Q3 financial reports of MNCs have been released one after another, and some are happy and some are sad. When a number of MNCs began to lower their full-year EPS, Amgen’s Q3 financial report earnings gave a high score answer sheet. Among them, Amgen’s total revenue in the third quarter increased by 23%, and its GAAP net earnings per share (EPS) increased by 62% year-on-year, from US$3.22 to US$5.22. What is more imaginative is that with the data catalysis of the new macromolecular weight loss drug AMG133, this macromolecular antibody that goes against the grain and antagonizes GIPR may become Amgen’s next gold mine. According to Amgen’s Q3 2024 financial report, the most significant year-on-year growth is LUMAKRAS (AMG510) – a targeted drug for KRASG12C mutation-positive lung cancer. The sales ceiling of this gene mutation in European and American countries will be much higher than that in Asian ...
- Source: drugdu
- 59
- November 6, 2024
China’s time-honored brands, mergers and acquisitions accelerate

Recently, Beijing Tong Ren Tang issued an announcement on foreign investment, stating that its holding subsidiary Beijing Tong Ren Tang Commercial intends to sign a “Share Transfer Agreement” with Honghui Technology, Daopei Hongde, Honghui Pharmaceutical, Wang Desheng and Wang Aixiao, and intends to pay about 105 million yuan to acquire Honghui Technology’s 51% stake in Honghui Pharmaceutical. As a pharmaceutical and medical device operating company, Honghui Pharmaceutical was established in 1994 and is mainly engaged in pharmaceutical research and development, pharmaceutical production and sales, and medical device operations. The performance in the first half of 2024 showed that Honghui Pharmaceutical achieved revenue of 844 million yuan and net profit of 25.5713 million yuan (unaudited). In 2023, Honghui Pharmaceutical achieved a net profit of 228 million yuan (unaudited). At present, Honghui Pharmaceutical is still a long way from catching up with last year’s full-year net profit. Tong Ren Tang is a ...
- Source: drugdu
- 60
- November 6, 2024
NMN can prevent physical decline and poor sleep

Walking speed reflects the vitality of the muscles, bones, nerves and cardiovascular system, so our walking speed can also predict our lifespan. After the age of 65, our walking speed gradually decreases, and eventually our daily life will be affected, greatly reducing our quality of life. Therefore, it is very important to keep muscles, bones, nerves and heart healthy through endurance and resistance training. Exercise may be the best way to prevent slow walking. However, poor sleep quality and low energy levels may prevent many people from sticking with exercise. In addition, poor sleep quality and fatigue may be the cause of low NAD+ levels. Recently, Japanese scientists published a research article titled “Ingestion of β-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults in a double-blind randomized, placebo-controlled study” in the journal “GeroScience”. The results showed that supplementing NMN can prevent physical ...
- Source: drugdu
- 54
- November 6, 2024
The World’s First Targeted Innovative Drug for Hepatitis B Approved for Market

On October 30, Xi’an Xintong Pharmaceutical Research Co., Ltd. held a press conference in the Silk Road Innovation and Smart Valley of Xi’an High-tech Zone to announce the approval of “Xinshi Mu,” a first-class innovative drug targeting hepatitis B. It is the commercial name approved for the drug Preadfovir mesylate tablets, which is indicated for the treatment of chronic hepatitis B in adults. The drug utilizes the HepDirect liver-targeted delivery system to concentrate the active ingredients in the target organ, enhancing efficacy and reducing toxicity. This makes it the world’s first approved liver-targeted innovative drug for hepatitis B. Zhang Denge, chairman of Xintong Pharmaceutical, stated that “Xinshi Mu” is part of the national major new drug creation projects during the 12th and 13th Five-Year Plans, with research beginning in 2011, and it took 13 years to gain approval for market release. Wang Liping, the Drug Safety Director of the Shaanxi ...
- Source: drugdu
- 45
- November 6, 2024
$1.4 billion deal highlights the future of Alzheimer’s disease therapy

The development of therapies for Alzheimer’s disease has always caused many developers to feel exhausted, and now AbbVie has also increased its investment in neurodegenerative diseases. AbbVie has agreed to spend $1.4 billion to acquire Aliada Therapeutics, whose main acquisition asset is Aliada’s authorized Alzheimer’s disease candidate drug ALIA-1758 from Johnson&Johnson. Its mechanism of action is still an anti beta amyloid protein (3pE-A β) antibody, but the unique feature of ALIA-1758 is that it can cross the blood-brain barrier, greatly improving the brain’s absorption rate. Aliada started a phase 1 trial among healthy volunteers in May, but AbbVie believes the timing is ripe for acquisition. Previously, AbbVie made the decision to abandon its internal Alzheimer’s disease asset ABBV-916. This anti beta amyloid antibody has no significant difference in safety and efficacy compared to the already marketed monoclonal antibody therapy for Alzheimer’s disease. Therefore, AbbVie decided to terminate the development ...
- Source: drugdu
- 55
- November 5, 2024
Interphex

Organiser：Pharmaceutical Research and Manufacturers of America (PhRMA) Time： April 1st – 3rd, 2025 Address：655 West 34th Street, New York, NY 10001-1188, USA Exhibition hall：Javits Convention Center, NYC Product range: Active Pharmaceutical Ingredients (APIs): Vitamins, hormones, cephalosporins, macrolides, central nervous system drugs, and other western medicine raw materials Excipients & Dosage Forms: Excipients, fluids, enteric coatings, antioxidants, sweeteners, osmotic agents, preservatives, disintegrants, clarifiers, pH adjusters, etc. Natural Extracts: Plant extracts, animal extracts, dietary fibers, cosmetic ingredients About Interphex： Interphex, the Biopharmaceutical Manufacturing & Technology Exhibition in New York, USA, is a leading event in the pharmaceutical and biotechnology industries, merging industry innovations with expert-led conferences. Since its inception in 1979, it has been the most trusted life science exhibition across both chemical and biopharmaceutical sectors in North America. Exhibitors have the opportunity to meet with decision-makers from top pharmaceutical companies worldwide through this exhibition.
- Source: drugdu
- 61
- November 5, 2024
Johnson&Johnson announces latest personnel changes

Recently, Larry Jones, Global Vice President and Group Chief Information Officer of Medical Technology at Johnson&Johnson (NYSE: JNJ), will leave the world’s second-largest medical device manufacturer. He will retire from Johnson&Johnson’s medical device business. The details of when and when the official resignation will take place, or who will take over, are still unknown. 01. Retirement of Group Chief Information Officer Recently, Larry Jones announced that he will retire from Johnson&Johnson’s medical device business. When asked when he will officially resign or if someone will replace him, he said he will share more details when the information becomes public. Johnson&Johnson Medical Technology did not respond to further information requests. Jones is a goal oriented leader who achieves transformational change through key principles such as business process integration, agile methods, and next-generation technology solutions. He focuses on driving digital surgical connectivity solutions for Johnson&Johnson’s oncology, orthopedics, cardiovascular, and general surgery robots ...
- Source: drugdu
- 47
- November 5, 2024
Sonavex announces completion of new round of financing

According to the Medicine Intelligence Data Investment Pattern Database, Sonavex, an innovative ultrasound technology company, recently announced the completion of a $15 million (contract RMB 106 million) Series A-2 financing to support its ultrasound technology. This round of financing has attracted several new investors and received strong participation from existing shareholders and industry veterans. Sonavex is a medical device company located in Baltimore, Maryland, spun off from Johns Hopkins University. Sonavex focuses on developing innovative ultrasound solutions to provide critical visual and quantitative data, improve patient treatment outcomes, and reduce healthcare costs. Medical ultrasound technology is a crucial imaging diagnostic tool in modern medicine, playing a crucial role in clinical diagnosis and treatment. However, there are still some technical limitations in traditional ultrasound technology, such as limited resolution and imaging quality due to factors such as sound wave frequency and probe size; Real time imaging and high frame rate are ...
- Source: drugdu
- 42
- November 5, 2024
Breaking news, Johnson & Johnson Medical Global Vice President resigns

Not long ago, Larry Jones, Global Vice President and Group Chief Information Officer of Johnson & Johnson MedTech, announced his decision to resign. On the LinkedIn platform, Jones recalled fondly: “Looking back on the 35 glorious years spent at Johnson & Johnson, my heart is filled with deep nostalgia for the extraordinary times we have gone through together.” During his tenure in Johnson & Johnson’s medical device department, Jones was particularly committed to promoting the company’s innovation in oncology, orthopedics, cardiovascular and general surgery, and realizing the innovation of digital surgical connection solutions through advanced technologies such as surgical robots and machine learning platforms. As a senior technology executive, Jones has rich leadership experience. During his decades in office, he has led many major projects in Johnson & Johnson’s pharmaceutical and medical device departments, including the recent three-year, $200 million global digital transformation plan. According to LinkedIn information, Jones is ...
- Source: drugdu
- 44
- November 5, 2024
COVID-19 drugs have become a “dark horse”

The success and failure of COVID-19 are the market’s summary of Pfizer in the past few years. In 2022, COVID-19 vaccines and COVID-19 oral drugs brought Pfizer up to $57 billion in revenue. Relying on the wealth brought by COVID-19 products, Pfizer’s revenue exceeded $100 billion this year, setting a new record for the highest revenue of major pharmaceutical companies. However, as the COVID-19 pandemic dissipated, the global market demand for COVID-19 products fell sharply, and Pfizer was the first to bear the brunt. Faced with the “COVID-19 cliff”, Pfizer had to continue to lower its revenue expectations, and the company’s stock price continued to fall. Last year, it fell by more than 40% throughout the year, and its market value evaporated by nearly $130 billion. In this year’s third quarter report, Pfizer handed in a report card that far exceeded market expectations. Revenue in the third quarter reached $17.7 ...
- Source: drugdu
- 45
- November 5, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.